Drug
Apatinib
Apatinib: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine, United Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Apatinib NCT02332512 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Apatinib NCT03651219 | Phase 3 | Small Cell Lung Cancer |
| Apatinib NCT03180476 | Phase 2 | Nasopharyngeal Neoplasms |
| Apatinib NCT01531777 | Phase 2 | Colorectal Cancer |
| Apatinib NCT03144843 | Phase 2 | Gastric Cancer |
| Apatinib Mesylate NCT04457180 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Apatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.